Meningitis appears in several past paper SAQs.
It is a topic which crosses the boundaries between infectious diseases questions (eg. "what organisms could be causing this?") and neurology questions ("explain this CSF picture").
One will therefore find the meningitis and encephalitis questions scattered rather arbitrarily between these two subject areas.
Meningitis is inflammation of the meninges and anything in the subarachnoid space. Encephalitis is an inflammation of the parenchyma itself, and sometimes gets referred to as "cerebritis".
A decreased level of consciousness suggests that the situation is serious; either there is increased intracranial pressure, or the sepsis is so advanced that some sort of encephalopathy has developed (however, one should point out that one of the criteria of diagnosis for septic encephalopathy is the absence of intracranial infection). Oh's Manual quotes mortality rates in excess of 90% for such bacterial meningitis. Thus, meningitis appears in the ICU only when it becomes interesting and complicated.
The main culprits in Australia are:
Apart from Listeria, the abovementioned bugs all spread by droplets and body fluid exposure. Beaman (2018, MJA) suggests that the top three in this list account for the majority of local cases. However, in Question 6.1 from the first paper of 2019 the college gives us a Southeast Asian teenager as a patient, raising the need to know the causes of meningitis in that geographic area. According to Chong & Tan (2005), bacterial meningitis in Hong Kong bacterial meningitis has a markedly different epidemiology, with the dominant pathogens being:
In the host who has been exposed to the ICU environment and has had some intrumentation of the brain, the range of possible infectious agents is broader:
One can also separate the pathogens by the age group and immune status of the host, as in Question 11 from the first paper of 2015.
Host group | Microbial enemies | Appropriate antibiotics (CICM model answer) |
Appropriate antibiotics (Therapeutic Guidelines) |
Neonates |
|
Ampicillin |
Cefotaxime + ampicillin |
Adults |
|
Ceftriaxone + Vancomycin |
Ceftriaxone or cefotaxime |
Immunosuppressed adults |
|
Vancomycin + Ampicillin + Cefepime or meropenem |
Ceftriaxone or cefotaxime + Benzylpenicillin for Listeria + vancomycin (most of the time) |
The elderly |
|
Ceftriaxone + Ampicillin + Vancomycin |
Ceftriaxone or cefotaxime + Benzylpenicillin for Listeria + vancomycin (most of the time) |
Therapeutic Guidelines recommend slightly different drugs; benzylpenicillin is substituted for ampicillin and vancomycin is only offered to those with unidentified gram positive cocci in their CSF, or whenever an LP is not available. Aminoglycosides are not mentioned. The neonates get cefotaxime instead of ceftriaxone, for some reason.
eTG give their references as the 2014 NSW Health guidelines, and this 2004 article by Tunkel et al from Clinical infectious diseases. It is unclear what happened to the candidates whose antibiotic choices agreed with Therapeutic Guidelines but not with the college.
Folk wisdom recommends against performing a lumbar puncture in a patient with increased intracranial pressure, with good reason. One does not wish to give the brainstem any reason to herniate. The 2004 published guidelines contain a often-quoted table of features which would make one want to exclude space-occupying lesions before performing an LP:
Oh's Manual only lists papilloedema seizures and focal neurological signs as contraindications to an LP.
Ohs Manual has a nice table on page 599 which outlines the expected CSF changes in bacterial and viral meningitis. The bacterial varierty will feature a low CSF glucose and a high CSF protein, with swarms of granulocytes in the CSF, whereas viral meningitis will have predominantly lymphocytes and not much protein. Meningitis caused by Listeria monocytogenes is slightly unique: the specific CSF finding is lymphocytosis of the CSF, which can con you into mistaking it for a viral meningitis (Brouwer et al, 2006). This comes up once in the exam, in Question 2 from the first paper of 2019.
Question 11.1 from the second paper of 2008 and Question 6.2 from the first paper of 2019 present the candidates with a dirty CSF sample, expecting them to conclude that the EVD is infected. The most likely organisms are usually visiting skin flora, such as Staphylococcus aureus, Staphylococcus epidermidis or Streptococcus pyogenes.
The two things one should immediately consider is
1) Get the infected EVD out
2) Start some antibiotics, which in the context of unknown sensitivities should consist of cephalosomething and vancomycin.
Apparently, anywhere between 4% and 20% of EVDs get infected. Other authors (Beer et al, 2008) put the figure as 2-27%. The Beer and Lackner article is the source for the following points:
There are several causes of meningitis which will not produce a positive Gram stain.
This topic enjoys a thorough exploration in this 2007 article. The table of infectious and noninfectious causes they produce is massive, and to reproduce it here would only serve to bewilder and depress the exam candidate.
Additionally, one might wish to consider non-infectious causes, such as lymphoma, vasculitis, or drug-induced meningitis (eg. due to cotrimoxazole or azathiaprine).
The damage to neurons in bacterial meningitis is thought to be partly due to the violent host response, with much of the irreversible damage done by migrating leukocytes. This is vaguely the same justification which was given for the use of high dose steroids for septic shock in the late 1980s. In the case of meningitis, it actually sort-of seems to work.
Though it is still a debated measure, most people these days give dexamethasone to meningitis patients. This practice is supported by a large Cochrane review by Van de Beek et al (2007), which analysed the evidence from 18 studies, involving 2750 patients, and concluded that "corticosteroids significantly reduced rates of mortality, severe hearing loss and neurological sequelae".
Six years later, the 2013 review by Brouwer et al (the same one quoted by the college in their model answer to Question 11 from the first paper of 2015) was able to include 4121 participants from twenty-five trials. There were some differences in their conclusions, in comparison to the previous meta-analysis:
Still, the overall conclusion that corticosteroids should still be given to patients in high-income countries.
Adverse effects of corticosteroids in meningitis are mentioned in this 1996 article by Townsend et al. In brief, the only major concern is that corticosteroids may rapidly normalise the blood brain barrier function, decreasing the penetration of antibiotics into the CSF. This phenomenon is known purely from rabbit models. Might I add that in those models the decreased concentration of ampicillin in the rabit CSF was still well above MIC for the E.coli they injected into the rabbits. In the one known human study (Paris et al, 1994) with eleven meningitic children the CSF concentration of ceftriaxone was also unaffected. In short, the evidence to feed these concerns is far from convincing.
In brief:
Oh's Intensive Care manual: Chapter 54 (pp. 597) Meningitis and encephalomyelitis by Angus M Kennedy
Beaman, Miles H. "Community‐acquired acute meningitis and encephalitis: a narrative review." Medical Journal Of Australia209.10 (2018): 449-454.
Van de Beek, D., et al. "Corticosteroids for acute bacterial meningitis."Cochrane Database Syst Rev 1 (2007).
Brouwer, Matthijs C., et al. "Corticosteroids for acute bacterial meningitis." Cochrane Database Syst Rev 6 (2013).
Lee, Bonita E., and H. Dele Davies. "Aseptic meningitis." Current opinion in infectious diseases 20.3 (2007): 272-277.
Beer, R., P. Lackner, and B. Pfausler. "Nosocomial ventriculitis and meningitis in neurocritical care patients." Journal of neurology 255.11 (2008): 1617-1624.
Korinek, A-M., et al. "Prevention of external ventricular drain–related ventriculitis." Acta neurochirurgica 147.1 (2005): 39-46.
NSW Health. Infants and children: acute management of bacterial meningitis: clinical practice guideline. North Sydney: NSW Ministry of Health; 2014.
Tunkel, Allan R., et al. "Practice guidelines for the management of bacterial meningitis." Clinical infectious diseases 39.9 (2004): 1267-1284.
Townsend, Gregory C., and W. Michael Scheld. "The use of corticosteroids in the management of bacterial meningitis in adults." Journal of Antimicrobial Chemotherapy 37.6 (1996): 1051-1061.
Paris, Maria M., et al. "Effect of dexamethasone on therapy of experimental penicillin-and cephalosporin-resistant pneumococcal meningitis." Antimicrobial agents and chemotherapy 38.6 (1994): 1320-1324.
Spapen, H., et al. "Adjunctive steroid treatment in acute bacterial meningitis." To do or not to do: That is the question"." (2014).
Hearmon, Christine J., and Salil K. Ghosh. "Listeria monocytogenes meningitis in previously healthy adults." Postgraduate medical journal 65.760 (1989): 74-78.
Chong, H. T., and C. T. Tan. "Epidemiology of central nervous system infections in Asia, recent trends." Neurology Asia 10 (2005): 7-11.